152 related articles for article (PubMed ID: 35696185)
1. Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
Teng E; Manser PT; Pickthorn K; Brunstein F; Blendstrup M; Sanabria Bohorquez S; Wildsmith KR; Toth B; Dolton M; Ramakrishnan V; Bobbala A; Sikkes SAM; Ward M; Fuji RN; Kerchner GA;
JAMA Neurol; 2022 Aug; 79(8):758-767. PubMed ID: 35696185
[TBL] [Abstract][Full Text] [Related]
2. Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.
Monteiro C; Toth B; Brunstein F; Bobbala A; Datta S; Ceniceros R; Sanabria Bohorquez SM; Anania VG; Wildsmith KR; Schauer SP; Lee J; Dolton MJ; Ramakrishnan V; Abramzon D; Teng E;
Neurology; 2023 Oct; 101(14):e1391-e1401. PubMed ID: 37643887
[TBL] [Abstract][Full Text] [Related]
3. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
Ostrowitzki S; Bittner T; Sink KM; Mackey H; Rabe C; Honig LS; Cassetta E; Woodward M; Boada M; van Dyck CH; Grimmer T; Selkoe DJ; Schneider A; Blondeau K; Hu N; Quartino A; Clayton D; Dolton M; Dang Y; Ostaszewski B; Sanabria-Bohórquez SM; Rabbia M; Toth B; Eichenlaub U; Smith J; Honigberg LA; Doody RS
JAMA Neurol; 2022 Nov; 79(11):1113-1121. PubMed ID: 36121669
[TBL] [Abstract][Full Text] [Related]
5. Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial.
Edwards AL; Collins JA; Junge C; Kordasiewicz H; Mignon L; Wu S; Li Y; Lin L; DuBois J; Hutchison RM; Ziogas N; Shulman M; Martarello L; Graham D; Lane R; Budd Haeberlein S; Beaver J
JAMA Neurol; 2023 Dec; 80(12):1344-1352. PubMed ID: 37902726
[TBL] [Abstract][Full Text] [Related]
6. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR; Zimmer JA; Evans CD; Lu M; Ardayfio P; Sparks J; Wessels AM; Shcherbinin S; Wang H; Monkul Nery ES; Collins EC; Solomon P; Salloway S; Apostolova LG; Hansson O; Ritchie C; Brooks DA; Mintun M; Skovronsky DM;
JAMA; 2023 Aug; 330(6):512-527. PubMed ID: 37459141
[TBL] [Abstract][Full Text] [Related]
7. Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial.
Tsai RM; Miller Z; Koestler M; Rojas JC; Ljubenkov PA; Rosen HJ; Rabinovici GD; Fagan AM; Cobigo Y; Brown JA; Jung JI; Hare E; Geldmacher DS; Natelson-Love M; McKinley EC; Luong PN; Chuu EL; Powers R; Mumford P; Wolf A; Wang P; Shamloo M; Miller BL; Roberson ED; Boxer AL
JAMA Neurol; 2020 Feb; 77(2):215-224. PubMed ID: 31710340
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
Wessels AM; Tariot PN; Zimmer JA; Selzler KJ; Bragg SM; Andersen SW; Landry J; Krull JH; Downing AM; Willis BA; Shcherbinin S; Mullen J; Barker P; Schumi J; Shering C; Matthews BR; Stern RA; Vellas B; Cohen S; MacSweeney E; Boada M; Sims JR
JAMA Neurol; 2020 Feb; 77(2):199-209. PubMed ID: 31764959
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
10. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial.
Craft S; Raman R; Chow TW; Rafii MS; Sun CK; Rissman RA; Donohue MC; Brewer JB; Jenkins C; Harless K; Gessert D; Aisen PS
JAMA Neurol; 2020 Sep; 77(9):1099-1109. PubMed ID: 32568367
[TBL] [Abstract][Full Text] [Related]
11. Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.
Coric V; Salloway S; van Dyck CH; Dubois B; Andreasen N; Brody M; Curtis C; Soininen H; Thein S; Shiovitz T; Pilcher G; Ferris S; Colby S; Kerselaers W; Dockens R; Soares H; Kaplita S; Luo F; Pachai C; Bracoud L; Mintun M; Grill JD; Marek K; Seibyl J; Cedarbaum JM; Albright C; Feldman HH; Berman RM
JAMA Neurol; 2015 Nov; 72(11):1324-33. PubMed ID: 26414022
[TBL] [Abstract][Full Text] [Related]
12. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
Ostrowitzki S; Lasser RA; Dorflinger E; Scheltens P; Barkhof F; Nikolcheva T; Ashford E; Retout S; Hofmann C; Delmar P; Klein G; Andjelkovic M; Dubois B; Boada M; Blennow K; Santarelli L; Fontoura P;
Alzheimers Res Ther; 2017 Dec; 9(1):95. PubMed ID: 29221491
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
Fleisher AS; Munsie LM; Perahia DGS; Andersen SW; Higgins IA; Hauck PM; Lo AC; Sims JR; Brys M; Mintun M;
Neurology; 2024 Mar; 102(5):e208061. PubMed ID: 38386949
[TBL] [Abstract][Full Text] [Related]
14. Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial.
Ljubenkov PA; Edwards L; Iaccarino L; La Joie R; Rojas JC; Koestler M; Harris B; Boeve BF; Borroni B; van Swieten JC; Grossman M; Pasquier F; Frisoni GB; Mummery CJ; Vandenberghe R; Le Ber I; Hannequin D; McGinnis SM; Auriacombe S; Onofrj M; Goodman IJ; Riordan HJ; Wisniewski G; Hesterman J; Marek K; Haynes BA; Patzke H; Koenig G; Hilt D; Moebius H; Boxer AL
JAMA Netw Open; 2021 Sep; 4(9):e2125584. PubMed ID: 34559230
[TBL] [Abstract][Full Text] [Related]
15. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
Lawlor B; Segurado R; Kennelly S; Olde Rikkert MGM; Howard R; Pasquier F; Börjesson-Hanson A; Tsolaki M; Lucca U; Molloy DW; Coen R; Riepe MW; Kálmán J; Kenny RA; Cregg F; O'Dwyer S; Walsh C; Adams J; Banzi R; Breuilh L; Daly L; Hendrix S; Aisen P; Gaynor S; Sheikhi A; Taekema DG; Verhey FR; Nemni R; Nobili F; Franceschi M; Frisoni G; Zanetti O; Konsta A; Anastasios O; Nenopoulou S; Tsolaki-Tagaraki F; Pakaski M; Dereeper O; de la Sayette V; Sénéchal O; Lavenu I; Devendeville A; Calais G; Crawford F; Mullan M;
PLoS Med; 2018 Sep; 15(9):e1002660. PubMed ID: 30248105
[TBL] [Abstract][Full Text] [Related]
16. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.
Pontecorvo MJ; Lu M; Burnham SC; Schade AE; Dage JL; Shcherbinin S; Collins EC; Sims JR; Mintun MA
JAMA Neurol; 2022 Dec; 79(12):1250-1259. PubMed ID: 36251300
[TBL] [Abstract][Full Text] [Related]
17. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
Shcherbinin S; Evans CD; Lu M; Andersen SW; Pontecorvo MJ; Willis BA; Gueorguieva I; Hauck PM; Brooks DA; Mintun MA; Sims JR
JAMA Neurol; 2022 Oct; 79(10):1015-1024. PubMed ID: 36094645
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
19. Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study.
Florian H; Wang D; Arnold SE; Boada M; Guo Q; Jin Z; Zheng H; Fisseha N; Kalluri HV; Rendenbach-Mueller B; Budur K; Gold M
Brain; 2023 Jun; 146(6):2275-2284. PubMed ID: 36730056
[TBL] [Abstract][Full Text] [Related]
20. TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease.
Shulman M; Kong J; O'Gorman J; Ratti E; Rajagovindan R; Viollet L; Huang E; Sharma S; Racine AM; Czerkowicz J; Graham D; Li Y; Hering H; Haeberlein SB
Nat Aging; 2023 Dec; 3(12):1591-1601. PubMed ID: 38012285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
